Your Liver Enzymes Are Normal—But Has Anyone Checked for Scarring?
A fatty liver diagnosis is easy to file away when the next round of bloodwork comes back “normal.” The ultrasound report goes into a drawer, the ALT and AST numbers settle down, and the issue starts to feel less urgent.
That was the part I wanted to understand more clearly. Does normal bloodwork mean the liver is no longer at risk, or could scarring be developing quietly while everything still looks fine on paper?
After going through current U.S. liver guidance, I found that the answer is not as simple as “normal” or “abnormal.” ALT and AST can help show whether liver cells are under stress, but they do not directly measure scar tissue. A person may have metabolic dysfunction-associated steatotic liver disease, or MASLD, and still develop meaningful fibrosis without dramatic symptoms or persistently high liver enzymes.
The question is no longer only, “Do I have fat in my liver?”
It is also, “Has anyone checked whether scar tissue has begun to form?”
• Fatty liver and liver fibrosis are not the same condition.
• Fibrosis means repeated liver injury has left scar tissue behind.
• Normal ALT and AST do not completely rule out significant scarring.
• FIB-4 uses age, AST, ALT, and platelet count to estimate fibrosis risk.
• FibroScan measures liver stiffness and may also estimate liver fat.
• F0 through F3 describe increasing fibrosis; F4 generally represents cirrhosis.
• An intermediate or high-risk result does not automatically mean cirrhosis.
• Diabetes, long-standing fatty liver, abdominal obesity, high triglycerides, and regular alcohol exposure can raise the need for a closer look.
A useful first step is to find your most recent liver panel, platelet count, and abdominal ultrasound report. Those three items can help your primary care clinician decide whether FIB-4, elastography, or a specialist referral makes sense.
1. How Fatty Liver Can Slowly Turn Into Liver Fibrosis
The liver is built to recover from short periods of stress. When an injury stops, damaged cells may be repaired and normal function can continue.
The trouble starts when the same kind of injury keeps returning. Insulin resistance, excess liver fat, poorly controlled diabetes, ongoing alcohol exposure, viral hepatitis, certain medications, and other liver conditions can repeatedly damage liver cells.
As the liver repairs those areas, it produces collagen and other structural material. That response is useful in the short term. When the cycle continues for years, the repair tissue can accumulate and become fibrosis.
Most people think of scar tissue as something that forms on the skin. The liver is not so different. When injury keeps happening, the repair process can gradually leave thicker, less flexible tissue behind. Over time, widespread scarring may begin to affect the liver’s normal structure and blood flow.
Does Everyone With Fatty Liver Develop Fibrosis?
No. Some people live with liver fat for years without developing advanced scarring. Others move from simple fat accumulation to inflammation, liver-cell injury, and fibrosis.
The difference often lies in the larger metabolic picture. A mild ultrasound finding may carry a very different meaning in someone with type 2 diabetes, rising triglycerides, abdominal weight gain, sleep apnea, or regular alcohol use than it does in someone without those risks.
- Type 2 diabetes or prediabetes
- Increasing waist circumference
- High triglycerides
- High blood pressure
- Obstructive sleep apnea
- Low physical activity
- Regular or heavy alcohol use
- Chronic hepatitis B or hepatitis C
- A family history of cirrhosis or liver cancer
Two people can both have “mild fatty liver” on an ultrasound and still face very different long-term risks. One may need routine metabolic follow-up. The other may need a fibrosis score, liver stiffness testing, or a specialist review.
This is where the blood sugar connection becomes important.
Understanding how muscle, insulin, and glucose handling affect liver fat helps explain why metabolic risk and fibrosis often travel together.
👉 GLUT4: The Hidden Metabolic Switch That May Change How You Think About Blood Sugar After 50
If fatty liver was first noted three or four years ago, it is worth pulling out that old report. The missing question may not be whether liver fat was present then, but whether anyone has checked for scarring since.
The important point is not that fatty liver always becomes cirrhosis. It does not. The concern is that repeated inflammation and injury can quietly change the liver long before a person feels seriously ill.
2. Why Liver Scarring Can Be Missed for Years
Most people expect serious liver disease to announce itself with obvious symptoms. Yellow eyes, severe abdominal pain, or a swollen belly are what usually come to mind.
In reality, liver fibrosis often develops much more quietly. Many adults continue working, traveling, exercising, and caring for their families without realizing that scar tissue may be slowly accumulating.
Some people notice fatigue, slower recovery after exercise, or a vague feeling of pressure beneath the right rib cage. Those symptoms alone cannot diagnose fibrosis because anemia, thyroid disease, poor sleep, medication effects, kidney disease, heart disease, or blood sugar problems can all produce similar complaints.
Looking at the entire pattern is far more valuable than focusing on one symptom.
Persistent fatigue becomes more meaningful when it appears together with diabetes, abdominal obesity, elevated triglycerides, previous fatty liver on ultrasound, gradually falling platelet counts, or a history of abnormal liver tests.
Why Normal ALT and AST Can Be Misleading
One of the biggest misunderstandings is assuming that normal liver enzymes automatically mean the liver is healthy.
ALT and AST are excellent markers of ongoing liver-cell injury, but they are not measurements of scar tissue. A normal result simply means there may not be significant enzyme leakage into the bloodstream at the moment the blood sample was taken.
Scar tissue that formed over many years may still remain even if today's liver enzymes are completely normal.
The National Institute of Diabetes and Digestive and Kidney Diseases explains that physicians often combine medical history, laboratory testing, imaging studies, elastography, and occasionally liver biopsy because no single blood test tells the entire story.
Normal liver enzymes can be reassuring.
They should never be considered a fibrosis test.
If your fatty liver was first discovered several years ago, this may be a good time to locate that original ultrasound report. The important question today may no longer be whether fat was present—it may be whether anyone has evaluated the possibility of fibrosis since then.
Many people continue searching for the cause of unexplained fatigue while overlooking changes that develop gradually over several years.
3. F0 Through F4: What the Fibrosis Stages Really Mean
Doctors commonly describe liver fibrosis using stages from F0 through F4. These stages originally came from examining liver tissue under a microscope, although modern noninvasive tests now help estimate where someone may fall along that spectrum.
It is important to remember that FIB-4 and FibroScan estimate risk—they do not automatically assign an exact biopsy stage. Age, inflammation, obesity, test quality, and the underlying liver condition all influence how results should be interpreted.
| Stage | Meaning | Typical Clinical Focus |
|---|---|---|
| F0 | No clear fibrosis | Reduce metabolic risk and prevent progression. |
| F1 | Mild fibrosis | Early scar tissue is present. Lifestyle intervention becomes especially valuable. |
| F2 | Moderate or significant fibrosis | Structured follow-up and specialist evaluation may be appropriate. |
| F3 | Advanced fibrosis | Higher risk of progression. Close monitoring is usually recommended. |
| F4 | Cirrhosis | Long-term surveillance for complications becomes part of ongoing care. |
Why F0 Still Deserves Attention
Many people assume an F0 result means the problem has disappeared. That is not necessarily true.
A person may still have MASLD, insulin resistance, diabetes, high triglycerides, or excess visceral fat despite having no detectable fibrosis today.
F0 represents an opportunity to prevent scar tissue—not a reason to ignore metabolic health.
Why F1 Can Be an Important Turning Point
Small amounts of scar tissue may already be forming, even when someone feels completely healthy.
This stage often offers the greatest opportunity to improve long-term liver health through gradual weight loss, regular physical activity, improved glucose control, limiting alcohol intake, and addressing sleep apnea when present.
Why F2 Changes Medical Decision-Making
Once fibrosis reaches F2, the discussion often becomes more structured.
Doctors may recommend closer follow-up, referral to a hepatologist or gastroenterologist, elastography, and consideration of therapies appropriate for patients with noncirrhotic MASH.
F2 does not mean cirrhosis—but it often changes how closely the liver should be monitored.
Understanding F3 and F4
F3 represents advanced fibrosis. Large areas of scar tissue begin connecting across the liver, making progression toward cirrhosis more likely if the underlying injury continues.
Some people with F3 still have preserved liver function and may feel surprisingly well.
F4 generally represents cirrhosis, where extensive scar tissue changes the liver's structure and blood flow. At this stage, long-term monitoring often includes screening for liver cancer, portal hypertension, esophageal varices, fluid retention, nutrition problems, and declining liver function.
The earlier fibrosis is identified, the more opportunities there may be to slow—or sometimes partially reverse—its progression.
4. FIB-4: The First Fibrosis Check May Already Be in Your Medical Record
FIB-4 sounds like a specialized liver test, but in many cases it is simply a calculation based on blood work you may already have.
Instead of requiring another blood draw, it combines four pieces of information that are commonly included in routine laboratory testing.
- Age
- AST
- ALT
- Platelet count
Current AASLD guidance recommends FIB-4 as one of the first noninvasive tools used to estimate fibrosis risk in adults with MASLD or metabolic risk factors.
Its main purpose is not to diagnose cirrhosis. It helps identify who appears to be at lower risk and who may benefit from additional evaluation.
What Does a Low FIB-4 Score Mean?
A low-risk result generally makes advanced fibrosis less likely at that moment.
It does not mean fatty liver has disappeared or that diabetes, obesity, insulin resistance, or elevated triglycerides no longer matter. If those risks remain, your clinician may recommend repeating the calculation in the future.
What Happens If the Score Is Intermediate?
An intermediate score is surprisingly common.
Rather than providing a clear answer, it suggests that another test may help clarify the situation.
The next step may include:
- FibroScan (transient elastography)
- Enhanced Liver Fibrosis (ELF) testing when available
- Magnetic Resonance Elastography (MRE)
- Additional blood-based fibrosis markers
- Referral to a gastroenterologist or hepatologist
An intermediate FIB-4 result is not the same as a diagnosis of cirrhosis.
Why Age Matters
Because age is built into the equation, FIB-4 scores naturally increase as people get older.
The calculation may also become less reliable during an acute illness or when liver enzymes rise temporarily because of infection, medication changes, or another short-term event.
Instead of relying on an online calculator alone, ask your clinician whether your laboratory results should be interpreted in the context of your overall metabolic health.
A simple question can move the conversation forward:
"My fatty liver has been present for several years. Should we review my AST, ALT, platelet count, and decide whether FIB-4 or liver stiffness testing would be appropriate?"
5. Ultrasound and FibroScan Answer Different Questions
Many people assume an abdominal ultrasound and FibroScan are interchangeable. They are not.
Although both evaluate the liver, they answer different clinical questions.
| Test | Primary Purpose | Main Limitation |
|---|---|---|
| Liver Panel | Shows liver-cell injury and aspects of liver function | Cannot measure fibrosis directly |
| FIB-4 | Estimates fibrosis risk | Cannot diagnose fibrosis by itself |
| Ultrasound | Detects liver fat, enlargement, masses and structural abnormalities | Limited ability to stage early fibrosis |
| FibroScan | Measures liver stiffness and estimates liver fat | Cannot determine the exact cause of stiffness |
| MR Elastography | Provides highly detailed stiffness assessment | Usually more expensive and less widely available |
| Liver Biopsy | Direct microscopic evaluation | Invasive and not necessary for most patients |
An abdominal ultrasound remains an excellent tool for identifying fatty liver, liver enlargement, gallbladder disease, masses, or obvious structural abnormalities.
What it does not do particularly well is measure early liver fibrosis.
FibroScan uses vibration-controlled transient elastography. A small probe sends a gentle vibration through the liver and measures how quickly the wave travels.
Stiffer liver tissue may suggest more fibrosis. Many modern systems also estimate liver fat using a Controlled Attenuation Parameter (CAP).
Ultrasound mainly shows how the liver looks.
FibroScan estimates how stiff it feels.
Can FibroScan Be Elevated Without Permanent Scarring?
Yes.
Liver stiffness can temporarily increase because of active inflammation, recent food intake, bile duct obstruction, congestive heart failure, technical limitations, severe obesity, or probe selection.
That is why interpreting one FibroScan number without medical context often creates unnecessary anxiety.
Doctors interpret liver stiffness together with your blood tests, medical history, ultrasound findings, metabolic risk factors, and the overall quality of the examination.
6. What Happens During a FibroScan Appointment?
One reason FibroScan has become increasingly popular is that it is quick, painless, and noninvasive.
No needles, anesthesia, contrast dye, or hospital admission are usually required.
You simply lie on your back with your right arm raised while the operator places a probe between the ribs on the right side of your abdomen.
Most people describe the sensation as a light tap against the skin rather than pain.
When good-quality measurements are obtained, the scan itself often takes only a few minutes.
In the United States, FibroScan is commonly available through hospital outpatient departments, gastroenterology clinics, hepatology practices, and independent imaging centers. Your primary care physician or liver specialist can help you choose the right setting based on your medical history, insurance network, and referral requirements.
Questions Worth Asking Before the Appointment
- How long should I fast before the test?
- Can I drink water?
- Should I take my regular medications?
- Will blood work be performed the same day?
- Will my results be reviewed immediately?
- Is the examination performed using FibroScan or another elastography system?
- Is this facility within my insurance network?
If you have diabetes, never stop insulin or prescription medication simply because fasting is required. Ask the clinic how medications should be managed before the appointment.
Those few questions can prevent unnecessary delays, unexpected bills, or the need to repeat the examination later.
7. When a Liver Specialist May Be Needed
For many adults, the evaluation begins with a primary care physician. Your clinician can review previous ultrasound reports, liver enzyme trends, metabolic risk factors, medications, alcohol use, and family history before deciding whether additional testing is necessary.
Many people never need a liver biopsy or immediate specialist care. Others benefit from seeing a gastroenterologist or hepatologist much earlier than they expected.
The goal of a referral is not simply to order more tests—it is to determine whether the next result would actually change treatment or long-term monitoring.
Situations That Often Lead to Referral
A specialist consultation becomes more likely when one or more of the following are present:
- Intermediate or elevated FIB-4 results
- FibroScan suggesting increased liver stiffness
- Gradually decreasing platelet counts
- Persistently elevated ALT or AST
- Abnormal bilirubin, albumin, or clotting studies
- Irregular or nodular liver appearance on imaging
- Enlarged spleen
- Evidence of portal hypertension
- Chronic hepatitis B or hepatitis C
- Uncertain cause of liver disease
- Suspected F2 or F3 MASH
- Possible cirrhosis
- Conflicting laboratory and imaging findings
Current guidance from the National Institute of Diabetes and Digestive and Kidney Diseases notes that liver biopsy is no longer the routine first step for everyone. In many cases, modern blood tests and elastography provide enough information to guide treatment decisions.
The right referral is not about doing more testing.
It is about choosing the test that answers the next important clinical question.
8. Why F2 and F3 Fibrosis Matter More Today
Lifestyle changes remain the foundation of treatment at every fibrosis stage. Healthy weight reduction, better glucose control, regular physical activity, triglyceride management, and avoiding additional liver injury continue to make the greatest long-term difference.
What has changed over the last few years is that prescription therapy is now available for selected adults with noncirrhotic MASH and moderate-to-advanced fibrosis.
Resmetirom (Rezdiffra)
In 2024, the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) for adults with noncirrhotic MASH and moderate-to-advanced fibrosis, generally corresponding to F2 and F3 disease.
The medication is intended to be used alongside nutrition, physical activity, and metabolic risk reduction—not instead of them.
It is not a general treatment for everyone with fatty liver.
Semaglutide
FDA approval was later expanded for selected adults with noncirrhotic MASH and moderate-to-advanced fibrosis using semaglutide-based therapy.
Eligibility depends on much more than liver fat alone. Clinicians also consider:
- Whether MASH is confirmed or strongly suspected
- The estimated fibrosis stage
- Whether cirrhosis is present
- Body weight and diabetes status
- Thyroid and liver laboratory findings
- Current medications and possible interactions
- Insurance authorization requirements
Treatment decisions today depend much more on fibrosis stage than they did only a few years ago.
Someone with F2 or F3 fibrosis may have treatment options that were not previously available, while someone with established cirrhosis often follows a very different management pathway.
A medication appropriate for noncirrhotic F2 or F3 disease should never be assumed to be appropriate for F4 cirrhosis.
People living with cirrhosis may require surveillance for liver cancer, portal hypertension, esophageal varices, fluid retention, malnutrition, and declining liver function in addition to treating the underlying liver disease.
9. FibroScan Cost, Medicare, and Private Insurance
One of the most common questions patients ask is simple:
"How much will this test actually cost me?"
Unfortunately, there is no single nationwide price for FibroScan or other liver stiffness tests.
For people paying out of pocket, costs can vary widely across the United States. A FibroScan may cost roughly $150–$500 without insurance, while MR elastography is often considerably more expensive, sometimes ranging from $700 to over $2,000. Actual charges depend on the facility, location, insurance plan, and whether additional laboratory or imaging tests are performed during the same visit.
Even within the same city, the cost of FibroScan can vary considerably between hospitals, outpatient imaging centers, and private specialty clinics.
Your out-of-pocket cost depends on several factors working together.
| Factor | Why It Matters |
|---|---|
| Facility | Hospital and outpatient centers often charge different rates. |
| Type of Elastography | FibroScan, ultrasound elastography, and MR elastography are billed differently. |
| Insurance Network | Out-of-network facilities may increase patient responsibility. |
| Medical Necessity | Coverage depends on your diagnosis and physician documentation. |
| Deductible & Coinsurance | Covered services may still require significant patient payment. |
| Prior Authorization | Some insurance plans require approval before testing. |
| Referral Requirements | Certain plans require a PCP referral before specialist testing. |
The Centers for Medicare & Medicaid Services (CMS) make an important distinction: having a billing code does not automatically guarantee Medicare payment. Coverage still depends on local policy, documentation, and medical necessity.
Questions Worth Asking Before Scheduling
- What is the exact name of the test?
- Is this FibroScan or another type of elastography?
- Which billing code will be submitted?
- Is prior authorization required?
- Is the physician in my insurance network?
- Do I need a referral from my primary care physician?
- What is the estimated self-pay cost?
- What will I likely owe after insurance?
Do not simply ask whether the test is "covered." Ask for your estimated out-of-pocket responsibility after deductibles and coinsurance.
Prescription therapy may require even more documentation, including laboratory results, fibrosis scores, FibroScan findings, physician notes, and confirmation that cirrhosis is not present.
For Medicare beneficiaries, Medicare Part B may cover medically necessary liver fibrosis evaluation when coverage criteria are met. People enrolled in Medicare Advantage (Part C) plans should remember that coverage, referral requirements, prior authorization, and out-of-pocket costs can vary between plans.
Because insurance policies continue to change, the most accurate estimate usually comes from both the treating office and your insurance company before the appointment is scheduled.
10. Can Liver Fibrosis Improve?
One of the most encouraging discoveries in recent years is that liver fibrosis is not always a one-way process.
When the underlying injury is reduced, early and moderate fibrosis may stabilize and, in some people, partially regress over time. How much improvement is possible depends on the original cause, the stage of fibrosis, diabetes control, body weight, alcohol exposure, medications, and overall metabolic health.
The earlier fibrosis is identified, the greater the opportunity to slow or even reverse part of the damage.
Weight Loss Protects More Than the Liver
For adults living with MASLD, gradual and sustainable weight reduction may lower liver fat, reduce inflammation, and improve fibrosis in selected patients.
Crash diets are rarely helpful. Adults over 50 also need to preserve muscle mass while losing fat, making adequate protein intake and resistance exercise especially important.
A practical eating pattern often includes:
- Fish, skinless poultry, eggs, beans, lentils, or tofu
- Vegetables and minimally processed foods
- Plain Greek yogurt
- Nuts and olive oil
- Smaller portions of refined carbohydrates
- Fewer sugar-sweetened beverages
- Less late-night eating
Movement Helps Even When the Scale Barely Changes
Exercise improves insulin sensitivity and helps muscles use glucose more efficiently, reducing one of the major drivers of fatty liver disease.
Helpful activities may include:
- Walking for 10–15 minutes after meals
- Stationary cycling
- Swimming or water aerobics
- Resistance-band training
- Strength training at least twice weekly when appropriate
Even modest increases in daily movement can improve metabolic health long before dramatic weight loss occurs.
Should You Take Liver Supplements?
Many supplements promise to "cleanse" or "repair" the liver, but current evidence does not support assuming that milk thistle, turmeric extracts, detox powders, green tea concentrates, or herbal blends can reverse fibrosis.
Some concentrated products may even interact with prescription medications or contribute to liver injury.
Before purchasing any supplement, review:
- The exact active ingredient and dose
- Whether individual ingredient amounts are clearly listed
- Good Manufacturing Practice (GMP) certification
- Independent verification such as USP or NSF when available
- Possible interactions with diabetes medication, statins, anticoagulants, or thyroid medicine
Supplements should never replace proper fibrosis evaluation or medical treatment.
Bring these three items whenever possible:
- Your most recent liver panel
- Your latest platelet count
- Your newest abdominal ultrasound report
- When fatty liver was first diagnosed
- Your latest A1C and triglyceride values
- Whether you have diabetes, prediabetes, or high blood pressure
- Your usual alcohol intake
- Every prescription medication, vitamin, herbal product, tea, or supplement you use
These details do not diagnose fibrosis, but they help your clinician decide whether FIB-4, FibroScan, or specialist evaluation is appropriate.
Seek prompt medical evaluation if you notice:
- Yellowing of the eyes or skin
- Dark urine or unusually pale stools
- Increasing abdominal swelling
- New leg swelling
- Significant loss of appetite
- Unexplained weight loss
- Easy bruising or unusual bleeding
- Vomiting blood
- Black, tarry stools
- New confusion or unusual sleepiness
- Fainting
- Severe abdominal pain with fever
- Rapidly increasing abdominal swelling
- Difficulty breathing
Conclusion
Fatty liver and liver fibrosis are closely related, but they answer different questions.
Fat in the liver may improve over time. Fibrosis reflects the scar tissue left behind after repeated injury, and that process may continue even when liver enzymes appear normal.
ALT and AST remain valuable tests, but they cannot measure scar tissue by themselves. FIB-4 helps estimate who may need additional evaluation, while FibroScan and other elastography techniques provide more information about liver stiffness.
The most important next step is not ordering every available liver test.
It is deciding whether your current risk factors justify the next appropriate test.
Before your next appointment, locate your previous ultrasound report, recent blood work, and medication list. A few minutes of preparation can completely change the conversation.
Instead of hearing only, "Your liver enzymes look normal," you can ask a much more meaningful question:
"Do we have enough information to know whether my liver has begun to scar?"
Frequently Asked Questions
Can liver fibrosis exist even if ALT and AST are normal?
Yes. ALT and AST reflect liver-cell injury, not the amount of scar tissue. Some people with clinically important fibrosis have normal or only mildly elevated enzyme levels.
Does a high FIB-4 score mean I have cirrhosis?
No. FIB-4 is a screening tool. Intermediate or elevated results usually indicate that additional testing such as FibroScan or specialist evaluation may be appropriate.
Is FibroScan better than an ultrasound?
They provide different information. Ultrasound evaluates liver structure and fat, while FibroScan estimates liver stiffness that may reflect fibrosis.
Can F2 or F3 fibrosis be treated?
Yes. Lifestyle modification remains essential, and selected adults with noncirrhotic MASH and F2–F3 fibrosis may also qualify for FDA-approved prescription therapy.
Will Medicare or private insurance cover FibroScan?
Coverage depends on medical necessity, insurance policy, diagnosis coding, network status, and local coverage rules. Always verify expected out-of-pocket costs before scheduling.
👉 Related Articles
👉 The Fasting Blood Sugar Illusion: Why Your "Normal" Lab Results Can Still Drain Your Daily Energy
👉 The Silent Interception: 10 Subtle Signs Your Body Is Battling Prediabetes Long Before Diagnosis
👉 Beyond Calories After 50 | Why Hormones, Sleep, and Circadian Rhythm Shape Your Metabolism
👉 Why Blood Vessels Age Faster After 50 — And How Red Foods May Help Protect Them
📚 Professional References
American Association for the Study of Liver Diseases (AASLD) — Clinical Practice Guidance on MASLD and Noninvasive Liver Disease Assessment.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) — Diagnosis and Evaluation of MASLD and Liver Fibrosis.
U.S. Food and Drug Administration (FDA) — Rezdiffra (Resmetirom) Approval Information.
U.S. Food and Drug Administration (FDA) — Wegovy (Semaglutide) MASH Indication Update.
Centers for Medicare & Medicaid Services (CMS) — Medicare Coverage Policies for Diagnostic Testing.
🩺 Medical Disclaimer
This article is intended for general educational purposes only and should not be used to diagnose or treat liver disease.
Blood tests, FIB-4, FibroScan, elastography, MRI, and liver biopsy each provide different information and should always be interpreted by a qualified healthcare professional.
Never start, stop, or change prescription medications, diabetes treatment, cholesterol therapy, alcohol-use treatment, or dietary supplements based solely on information in this article. Seek immediate medical care for jaundice, vomiting blood, black stools, rapidly increasing abdominal swelling, severe abdominal pain, fainting, or new confusion.
#LiverFibrosis #FibroScan #FIB4 #FattyLiver #MASLD #MASH #Cirrhosis #LiverEnzymes #NormalALT #NormalAST #LiverHealth #MetabolicHealth #HealthyAging #PreventiveCare #Type2Diabetes #InsulinResistance #Medicare #HealthAfter50 #VitalFactsHealth
Comments
Post a Comment